Options for primary chemotherapy of XXXX : @entity6023 .

@entity43 @entity1665 @entity3933 @entity137 @entity6023 @entity4444 @entity902 @entity1 @entity5 @entity4 @entity900 @entity1311 @entity786 @entity619 @entity1398 @entity56 @entity1431 @entity1205 @entity2359
The @entity6023 , a new class of anticancer agents, act by promoting the assembly of microtubules and stabilizing formed tubules. Two @entity6023 , @entity1311 and @entity1205 , have clinical activity in epithelial @entity43 , including @entity5 with @entity902 resistance. @entity137 associated with the @entity6023 include @entity56 , @entity1431 , @entity2359 , and @entity1665 . Premedication with @entity619 , @entity3933 , and @entity4444 decreases the incidence of severe anaphylactic reactions to less than 3%. In Phase II studies, response rates to @entity1311 in @entity1 with previously treated @entity43 ranged from 20 to 48%. To date, only two Phase III study using @entity1311 in the treatment of @entity43 have mature data. In one trial in @entity1 with @entity43 , conducted by the Gynecologic Oncology Group, @entity1 receiving @entity1311 / @entity900 had a significantly greater clinical response rate and surgical response rate and a significantly smaller risk of progression than those of @entity1 receiving @entity900 / @entity786 . In a Phase III study of @entity1311 in previously treated @entity1 at two different schedules (3- and 24-hr infusions), conducted by the Canadian-European Taxol Cooperative Group, @entity1 on the 24-hr infusion experienced significantly more grade 4 @entity1398 than those receiving the 3-hr infusion. The optimal dose, schedule, and combination for @entity1311 in the treatment of @entity1 with @entity43 have not yet been defined. In Phase II studies of @entity1205 in @entity1 with previously treated @entity43 , response rates of 33-35% were noted. Peripheral @entity4 was noted to be a clinically significant @entity137 .
